

Dr Louis Clearkin

CV

PRINCIPAL PROFESSIONAL SPECIALISMS

Consultant Ophthalmologist

ChM, FRCS, FRCOphth, DO

QUALIFICATIONS & ACCREDITATION

- Bachelor of Medicine and Surgery (MB ChB) University of Sheffield, 1978
- Full Registration, General Medical Council, 1979
- Diploma in Ophthalmology, Royal College of Surgeons, London, 1982
- FRCS, Royal College of Surgeons, London, 1983
- Certificate of Higher Surgical Training, Royal College of Surgeons, London, 1986
- FRCOphth, Royal College of Ophthalmologists, 1989
- ChM, University of Sheffield, 1992
- Ophthalmology Specialist Registration, General Medical Council, 1996
- International Member, American Academy of Ophthalmology, 2013
- Tier 1 Expert, Association of Personal Injury Lawyers, 2014
- FRCS Glasg, Royal College of Physicians and Surgeons, Glasgow, 2020
- Full Specialist Registration, Irish Medical Council, 2021

PAST & PRESENT POSITIONS

- **Consultant Ophthalmologist**, Royal Free London NHS Foundation Trust, 2024–2026
- **Member, TARGET Consortium**, Leeds Institute for Data Analytics, 2018–present
- **Research Associate in Risk and Uncertainty**, University of Liverpool, 2017–present
- **Sometime Visiting Lecturer in Physic**, Gresham College London, 2016–present
- **Associate Professor of Ophthalmology**, Ohio State University, 1999–present
- **Adjunct Professor of Ophthalmology**, St George's University, Grenada, 1987–present
- **Consultant Ophthalmologist**, Oxford University Hospitals, 2022–2023
- **Consultant Ophthalmologist**, Nottingham University Hospitals, 2021–2022
- **Surgical Trainer**, North-West School of Ophthalmology, 2020–2021
- **Consultant Ophthalmologist**, Liverpool University Hospitals, 2019–2021
- **Honorary Lecturer in Ophthalmology**, University of Liverpool, 1992–2021
- **Consultant Ophthalmic Surgeon**, Wirral University Teaching Hospital, 1992–2020
- **Volunteer Surgical Faculty**, ORBIS International, 1987–1997
- **Lecturer in Ophthalmology**, University of Sheffield, 1988–1992
- **Consultant Ophthalmic Surgeon**, Barnsley DHA, 1988–1992
- **Consultant Ophthalmic Surgeon**, St John's Hospital, Jerusalem, 1991

ABOUT DR CLEARLIN

Dr Louis Clearkin is an Expert Witness in Ophthalmology with a special interest in neuro-ophthalmology. He accepts claimant, defendant and joint instructions in civil litigation matters within his sphere of expertise, providing prompt, high-quality medical reports, with a faster turnaround available in urgent cases.

His medico-legal work includes the assessment and documentation of contentious or disputed visual injury, supported by access to diagnostic services including refraction, visual fields, retinal and corneal imaging, ocular electrophysiology, orthoptics and biometry.

Dr Clearkin is listed in The UK Law Society's Directory of Expert Witnesses, is a practising member of The Academy of Experts, a Tier 1 Expert with the Association of Personal Injury Lawyers, and provides advisory reports in professional disciplinary and regulatory matters.



NRC
MEDICAL EXPERTS

www.nnrc.org.uk
enquiries@nnrc.org.uk
0191 466 1406

Dr Louis Clearkin

CV

MEMBERSHIPS OF PROFESSIONAL BODIES

- General Medical Council
- Irish Medical Council
- Royal College of Surgeons of London
- Royal College of Ophthalmologists
- Royal College of Physicians and Surgeons of Glasgow
- American Academy of Ophthalmology
- British Medical Association
- North of England Ophthalmological Society
- Oxford Ophthalmological Congress
- United Kingdom Intraocular Implant Society
- Academy of Experts
- British Ophthalmic Anaesthesia Association
- American Society of Retina Specialists
- Faculty of Forensic and Legal Medicine
- Functional Neurological Disorders Society
- UK Psychological Trauma Society
- The Institute for Addressing Strangulation
- General Optical Council Advisor
- The Balint Society
- ORBIS International
- Institute for Risk and Uncertainty, University of Liverpool
- TARGET Consortium, Leeds Institute for Data Analytics

PRESENTATIONS TO LEARNED SOCIETIES

- Legal principles in Consent. North of England Ophthalmology Society, Haydock, 2026.
- Metadiagnosis; a remedy to overdiagnosis? (presentation) Preventing Overdiagnosis Conference, Oxford 2025
- Current evidence base for immune modulation in uveitis (presentation) Oxford Ophthalmological Congress 2024
- Giant Cell Arteritis Diagnosis: Metadiagnosis by robust-Bayesian estimate of strength of belief (poster). Oxford Ophthalmological Congress 2022
- Diagnosis of GCA; robust Bayesian actuarial estimation of personalised probability. North of England Ophthalmological Society March 2022.

PRESENTATIONS CONT.

- Risk estimation, Risk communication - a bluffers guide. Liverpool Risk Institute (Online) 2020
- Diagnosis of Giant-cell arteritis suspects: identifying the non-sufferers using Bayesian
- predictive modelling. Oxford Ophthalmology Congress: June 2018:
- CNV interventions: risk-benefit communication The RCOphth Annual Congress Liverpool 2018
- Understanding Risk-v-Benefit Risk in Medicine Wolfson Centre for Personalised Medicine 2017.
- Van Eyck's The Virgin with the Canon: Visual Disability and Societal Attitudes as Depicted in
- the Northern Renaissance. Gresham College October 2016
- Clinical Decision Support System for Chronic Ocular Discomfort Annual Meeting of the UKISCRS October 2015
- Absolute risk reduction and Natural frequencies in neo-vascular AMD. Oxford Ophthalmology Congress June 2015
- Decoding landmark studies in Ocular Hypertension and Glaucoma. North of England Ophthalmological Society, March 2015
- Web-based diagnosis. The Royal College of Ophthalmologists Clinical Leads Forum November 2014
- Prospects for online disease management, Westminster Health Forum Seminar October 2012
- Sequential treatment of macular oedema from retinal vascular occlusions and uveitis with anti-vegef agents and ozurdex. 7th Pan-Hellenic Vitreo-Retinal Conference Athens, May 2012
- Measuring the service impact of Ranibizumab treatment for macular degeneration. The Royal College of Ophthalmologists Annual Congress Liverpool January 2012
- Two-year follow-up of routine usage of 5-Fluoruracil to "enhance" trabeculectomy. European Glaucoma Society Congress Madrid Sept 2010.
- Cataract risk evaluation. HRA Medico-Legal Conference –Bristol December 2010
- Relation of Optical Coherence Tomography Features of Choroidal Neovascularization with Fluorescein Angiographic Appearance. ARVO, April 2009
- Giant Cell Arteritis: Are we over treating with corticosteroids? The Royal College of Ophthalmologists Annual Congress Liverpool June 2008
- Relevant Training Courses Attended
- The Functional Neurological Disorder Society 5th International Conference training day June 2024
- UK psychological Trauma Society Annual Conference, Oxford 2024
- Balint Spring Event (Online) March, 2022
- Neuroophthalmology Society Annual Meeting, Sheffield 2022
- Primary Angle Closure Fundamentals (online) AAO, 2021
- Asynchronous Telemedicine, Evolutio-Ophthalmology, 2021
- Practical Guidance for GDPR, Academy of Experts (online) 2021
- Ophthalmic Ultrasound Course, Birmingham and Midland Eye Centre, 2019
- Expert Elicitation, University of Liverpool, 2019
- TARGET GCA Symposium, University of Leeds, 2019

Dr Louis Clearkin

CV

ORIGINAL, PEER- REVIEWED ARTICLES

- Giant Cell Arteritis Diagnosis: Metadiagnosis by robust Bayesian estimate of strength of belief. *Rheumatology*. 2023;62(Supplement_2):kead104.096.
- Gray N, Calleja D, Wimbush A, Miralles-Dolz E, Gray A, De Angelis M, Derrer-Merk E, Oparaji BU, Stepanov V, Clearkin L, Ferson S. Is "no test is better than a bad test"? Impact of diagnostic uncertainty in mass testing on the spread of COVID-19. *PLoS One*. 2020;15(10):e0240775.
- Oparaji BU, Clearkin L, Ferson S, Angelis M, Ferrer-Fernandez M, Calleja D, Gray N, Derrer-Merk E. Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. *Rheumatology*. 2020;59(12):e159.
- Clearkin L, Ramasamy, Wason J, Tiew S. Anti-VEGF intervention in neovascular AMD: benefits and risks restated as natural frequencies. *BMJ Open Ophthalmology*. 2019;4(1):e000257.
- Clearkin L. Concerns over efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. *European Journal of Ophthalmology*. 2017.
- Clearkin L. Changes to the law on consent following Montgomery vs Lanarkshire Health Board. *British Journal of Hospital Medicine*. 2016;77(6):355-357.
- Clearkin L, Wason J, Tiew S. Latanoprost for open-angle glaucoma: a randomised, multicentre, placebo-controlled trial. *Lancet*. 2015.
- Glassman PJ, Clearkin LG. Visual loss and retinal vein occlusion: have we lost sight of the problem? *IJOR*. 2015;1(1):34-35.
- Clearkin L. Comment on "Herpes zoster ophthalmicus reduction: implementation of shingles vaccination in the UK". *Eye*. 2014;28(12):1522-1523.
- Clearkin L, Prasad S. Further advantage of SBCS. *Eye*. 2010;24(12):1829.
- Clearkin L. Powerless doctors. *The Times*. 22 September 2010.
- Stewart RM, Clearkin LG. Editorial: Insulin resistance and autoregulatory dysfunction in glaucoma and retinal vein occlusion. *American Journal of Ophthalmology*. 2010;145(3):394-396.

ARTICLES CONT.

- Stewart RM, Clearkin LG. Intercurrent factors associated with the development of open-angle glaucoma in the European glaucoma prevention study. *American Journal of Ophthalmology*. 2008;145(1):182.
- Durnian JM, Clearkin LG. Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss: could scanning laser polarimetry aid diagnosis? *Eye*. 2008;22(4):559-563.
- Topouzis F, Clearkin LG et al. A 1-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once-daily latanoprost 0.005%/timolol 0.5%. *European Journal of Ophthalmology*. 2007;17(2):183-190.
- Durnian JM, Clearkin LG. Gabapentin may cause reversible visual field constriction: GABA transaminase inhibitors may cause irreversible visual field loss. *BMJ*. 2006;332(7556):1511.
- Dhir L, Khan J, Dhir S, Clearkin LG. Relation of Optical Coherence Tomography Features of Choroidal Neovascularization with Fluorescein Angiographic Appearance. *Investigative Ophthalmology and Visual Science*. 2006;47:E-Abstract 5690.
- Clearkin LG. Twin fingerprints. *New Scientist*. 2005;2519:19.
- Harun S, Clearkin LG. Birdshot chorioretinopathy. *Ophthalmology*. 2005;112(3):527-528.
- Chuah C, Clearkin L. Mortality and non-ocular morbidity following cataract surgery under local anaesthesia compared to general anaesthesia. *Anaesthesia*. 2004;59:205-208.
- Murthy S, Clearkin LG. The National Survey of trabeculectomy. II. Variations in the operative technique and outcome. *Eye*. 2002;16(5):677-678.
- Sen J, Kamath GG, Clearkin LG. Surgically induced diffuse scleritis: comparison of incidence in phacoemulsification and conventional extracapsular cataract extraction. *British Journal of Ophthalmology*. 2002;86(6):701.
- Gallagher MJ, Clearkin LG. Subclinical hypothyroidism: increased awareness may prevent unnecessary treatment and morbidity. *Eye*. 2002;16(2):208-209.
- Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Prevalence of blindness and visual impairment in a population of people with diabetes. *Eye*. 2001;15(Pt 5):640-643.
- Prasad S, Kamath GG, Jones K, Clearkin LG, Phillips RP. Effectiveness of optometrist screening for diabetic retinopathy using slit-lamp biomicroscopy. *Eye*. 2001;15(Pt 5):595-601.
- Morgan JP, Clearkin LG. Rapid onset of ptosis indicates accurate intraconal placement during retrobulbar anaesthetic injection. *British Journal of Ophthalmology*. 2001;85(3):363-365.
- Gallagher MJ, Clearkin LG. Drug or drusen? Central retinal vein occlusion in a young healthy woman with disc drusen. *Eye*. 2000;14(Pt 3A):401-402.
- Kamath GG, Kent D, Clearkin LG. Conjunctivitis: sometimes more than meets the eye. *Eye*. 2000;14(Pt 1):102-103.
- Gallagher MJ, Clearkin LG, Watts MT. Cellulitis: an underestimated clinical entity. *BMJ Online*. 1999.
- Prasad S, Bannon P, Clearkin LG, Phillips RP. Digital fundus imaging: a quality and cost comparison with 35-mm film. *Acta Ophthalmologica Scandinavica*. 1999;77(1):79-82.
- Roberts E, Morgan R, King D, Clearkin L. Funduscopy: a forgotten art? *Postgraduate Medical Journal*. 1999;75(883):282-284.

Dr Louis Clearkin

CV

ARTICLES CONT.

- Kamath GG, Prasad S, Clearkin LG. The National Survey of Local Anaesthesia for Ocular Surgery. *Eye*. 1999;13(Pt 6):810-811.
- Kamath G, Prasad S, Clearkin L. National survey of local anaesthesia for ocular surgery. *Eye*. 1998;12(Pt 3a):489.
- Prasad S, Kamath GG, Clearkin LG. Primary angle-closure glaucoma in India. *Lancet*. 1998;352(9122):146.
- Yang YC, Hulbert MF, Batterbury M, Clearkin LG. Pulsatile ocular blood flow measurements in healthy eyes: reproducibility and reference values. *Journal of Glaucoma*. 1997;6(3):175-179.
- Chittenden HB, Clearkin LG, Sidky K. Herpes zoster ophthalmicus masquerading as giant cell arteritis. *British Journal of Hospital Medicine*. 1995;54(1):49-50.
- Clearkin L. Adverse effects of topical antiglaucoma medication. *Archives of Ophthalmology*. 1995;113(7):849-850.
- Clearkin L. The sight test fee: effectiveness of treatment for glaucoma remains unproved. *BMJ*. 1994;309(6965).
- Scott JA, Clearkin LG. Surgically induced diffuse scleritis following cataract surgery. *Eye*. 1994;8(Pt 3):292-297.
- Price N, Clearkin LG. Thrombocytosis and giant cell arteritis. *Lancet*. 1994;343(8898):672.
- Caballero JC, Clearkin LG. Complications of 5-fluorouracil after trabeculectomy. *Eye*. 1992;6(Pt 6):667.
- Clearkin LG. IV steroids for central retinal artery occlusion in giant-cell arteritis. *Ophthalmology*. 1992;99(10):1482-1484.
- Lockwood A, Clearkin LG. Insulin resistance in retinal vein occlusion and glaucoma. *Lancet*. 1992;340(8827):1100-1101.
- Clearkin LG. Giant cell arteritis. *BMJ*. 1992;305(6852):524.
- Clearkin L, Caballero J. Recovery of visual function in anterior ischemic optic neuropathy due to giant cell arteritis. *American Journal of Medicine*. 1992;92(6):703-704.
- Clearkin LG. Angle closure glaucoma precipitated by atropine. *Archives of Internal Medicine*. 1992;152(4):880.
- Clearkin L. Treatable blindness in temporal arteritis. *British Journal of Ophthalmology*. 1992;76(1):63-64.
- Scott JA, Clearkin LG. Optic neuropathy in endophthalmitis. *European Journal of Implant and Refractive Surgery*. 1992;4(3):195-197.
- Burke JP, Clearkin LG, Talbot JF. Recurrent corneal epithelial erosions in Alport's syndrome. *Acta Ophthalmologica*. 1991;69(4):555-557.

ARTICLES CONT.

- Clearkin LG, Watts MT. How to perform a temporal artery biopsy. *British Journal of Hospital Medicine*. 1991;46(3):172-174.
- Currie ZI, Lewis S, Clearkin LG. Dysthyroid eye disease masquerading as glaucoma. *Ophthalmic and Physiological Optics*. 1991;11(2):176-179.
- Watts MT, Greaves M, Rennie IG, Clearkin LG. Antiphospholipid antibodies in the aetiology of ischaemic optic neuropathy. *Eye*. 1991;5(Pt 1):75-79.
- Ansons AM, Benson C, Clearkin LG. Scleritis following intraocular lens implantation. *European Journal of Implant and Refractive Surgery*. 1991;3:261-265.
- Clearkin LG. Retinal detachment vs degenerative retinoschisis. *Archives of Ophthalmology*. 1990;108:657.
- Morton CE, Mallinson H, Clearkin LG, Ansons AM, Kaye LC, Mutton KJ. Per-nasal swabbing as an aid to the diagnosis of chlamydial and adenovirus conjunctivitis. *Eye*. 1990;4(Pt 3):510-513.
- Ansons AM, Clearkin L, Bryce I. Mechanisms leading to an acute rise in intraocular pressure in retinal vein occlusion. *Eye*. 1990;4(Pt 3):439-444.
- Clearkin LG, Watts MT. Ocular involvement in giant cell arteritis. *British Journal of Hospital Medicine*. 1990;43(5):373-376.
- Watts MT, Greaves M, Clearkin LG, Malia RG, Cooper SM. Anti-phospholipid antibodies and ischaemic optic neuropathy. *Lancet*. 1990;335(8689):613-614.
- Austin M, Clearkin LG. Radiological investigation in the management of uveitis. *Eye*. 1988;2:578-579.
- Harding SP, Mallinson H, Smith JL, Clearkin LG. Adult follicular conjunctivitis and neonatal ophthalmia in a Liverpool eye hospital, 1980-1984. *Eye*. 1987;1(Pt 4):512-521.
- Clearkin LG. Recent experience in the management of neovascular glaucoma by pan-retinal photocoagulation and trabeculectomy. *Eye*. 1987;1(Pt 3):397-400.
- Cole MD, Clearkin L, Dabbs T, Smerdon D. The seat belt law and after. *British Journal of Ophthalmology*. 1987;71(6):436-440.
- Belchetz PE, Carty A, Clearkin LG, Davis JC, Jeffreys RV, Rae PG. Failure of prophylactic surgery to avert massive pituitary expansion in pregnancy. *Clinical Endocrinology*. 1986;25(3):325-330.
- Clearkin IG, Rose H, Patterson A, Mody CH. Development of retinal arteriolar tortuosity in previously unaffected family members. *Transactions of the Ophthalmological Societies of the United Kingdom*. 1986;105(Pt 5):568-574.
- Clearkin L, Harding SP. Chlamydial ophthalmia neonatorum. *Midwives Chronicle*. 1986;99(1183):174-176.
- Clearkin LG, Hung SO. Acute posterior multifocal placoid pigment epitheliopathy associated with transient hearing loss. *Transactions of the Ophthalmological Societies of the United Kingdom*. 1983;103(Pt 5):562-564.
- Clearkin L, Harcourt B. Referral pattern of true and suspected glaucoma to an adult ophthalmic outpatient clinic. *Transactions of the Ophthalmological Societies of the United Kingdom*. 1983;103(Pt 3):284-287.